Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis
Liver International · 2026-04 · 46 (4)
DOI: 10.1111/liv.70610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 17.03.2026. Verfasst von Lars Bossen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Liver Cirrhosis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intercept Pharmaceuticals, Knud og Edith Eriksens Mindefond.
Abstract (Originalsprache)
Background & Aims Primary biliary cholangitis (PBC) is an autoimmune liver disease whose effect on long‐term survival remains unclear. We aimed to compare the prognosis of patients with biopsy‐confirmed PBC with population comparators.
Methods
We used nationwide healthcare registries to include all Danish patients diagnosed with histologically confirmed PBC in 1998–2020. We estimated the prevalence of PBC and the incidence in 2016–2019. Dividing PBC by presence or absence of cirrhosis, we used the cumulative incidence function to estimate the risk of death and HCC. We included 5:1 age‐ and sex‐matched population comparators.
Results
We included 1163 PBC patients (88.1% women, median age at diagnosis = 59.7 years); those with cirrhosis were older (median 63.9 vs. 59.0). Patients had more comorbidity at diagnosis than comparators, especially connective tissue disease. On January 1st 2021, the prevalence of PBC was 22.3 per 100,000 population. The incidence rate in 2016–2019 was 2.80 (95% CI: 2.58–3.02) per 100,000 population per year. PBC patients with cirrhosis had a higher 10‐year risk of death than their matched comparators, adjusted relative risk = 2.41 (95% CI: 1.89–3.09). For patients with non‐cirrhotic PBC, the 10‐year risk of death was 18.5% (95% CI: 15.5–21.7) versus 14.3% (95% CI: 13.0–15.6) for their comparators, adjusted relative risk = 1.22 (95% CI: 1.03–1.47). Patients with cirrhotic PBC had a 10‐year risk of HCC at 2.6% (95% CI: 0.8–6.0).
Conclusions
Patients with PBC have a worse prognosis than the general population irrespective of the presence or absence of cirrhosis at the time of PBC diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Internal Medicine, Horsens Regional Hospital, Horsens, Denmark.
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Lars Bossen
Förderung
- Intercept Pharmaceuticals
- Knud og Edith Eriksens Mindefond
Zitieren
APA
Bossen, L., Grønbæk, H., Ott, P., & Jepsen, P. (2026). Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis. Liver International, 46(4). https://doi.org/10.1111/liv.70610
Vancouver
Bossen L, Grønbæk H, Ott P, Jepsen P. Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis. Liver International. 2026;46(4). doi:10.1111/liv.70610
BibTeX
@article{Bossen2026,
author = {Bossen, Lars and Grønbæk, Henning and Ott, Peter and Jepsen, Peter},
title = {Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis},
journal = {Liver International},
year = {2026},
volume = {46},
number = {4},
doi = {10.1111/liv.70610}
}
EUVIMED